Danish consultancy companies NIRAS and AlfaNordic A/S are joining forces. The merger will strengthen both companies and give them the capacity to offer complete consultancy solutions for the life science business.
In recent years, NIRAS has experienced large growth in its consultancy services for the pharma and life science sector. By joining forces with another leading Danish consultancy company, AlfaNordic A/S, both companies will strengthen their capacity and thereby become the largest independent consultancy within the pharma and life science sector in Denmark.
NIRAS is working within a wide variety of sectors and has 2300 employees divided between 51 offices in 27 countries worldwide.
AlfaNordic A/S is a Danish high end GxP consulting firm with more than 90 employees. The company specializes in consultancy within production of pharmaceutical and biotech products, medical devices and food ingredients in relation to operational and quality processes. AlfaNordic is also a strategic provider of courses and young professional talents to business leading companies through the AlfaNordic Academy.
“By combining AlfaNordic’s strong skills and market position within GMP, validation, regulatory affairs, and quality assurance, with NIRAS’ expertise regarding the design of life science facilities and process plants, we will create a powerhouse within life science, and thereby also an inspiring environment for our employees. The merger with AlfaNordic gives both companies broader competencies, so we will now be able to offer complete solutions and consultancy to our customers,” says Thomas B. Olsen, senior vice president for Process Industry in NIRAS.
With its growth in recent years, NIRAS has strengthened its ambition of becoming a leading independent consultancy firm on the Danish life science market.
“AlfaNordic Academy is a strong asset for our life science clients, because we are training young professionals in GMP and other skills that are essential to the business. Furthermore, we are expecting to support the current growth of the Danish life science industry and to enhance the capacities of both our own specialists and the industry’s experts,” states Thomas B. Olsen.
AlfaNordic A/S is working for a large part of the Danish life science companies.
“AlfaNordic’s employees and customers will be benefit from this merger because the engineering and process skills of the two companies complement each other really well. Our combined knowledge of the industry will be strengthened and thereby both companies will achieve an even stronger position,” says Henrik Linnemann who is a senior partner in AlfaNordic.
Senior partner Thomas Meldgaard Petersen also thinks the merger with NIRAS will prove a clear advantage for both firms.
”Our employees will profit from becoming part of a larger professional environment which can help them develop their skills, and this will benefit both themselves and our clients,” says Thomas Meldgaard Petersen.